# A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

> **NCT04034095** · — · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 979 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Androgen-deprivation Therapy (ADT)
- **DRUG:** Bicalutamide
- **DRUG:** Abiraterone
- **DRUG:** Prednisolone
- **DRUG:** Docetaxel
- **DRUG:** Enzalutamide
- **DRUG:** Apalutamide

## Key facts

- **NCT ID:** NCT04034095
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-08
- **Primary completion:** 2024-08-13
- **Final completion:** 2024-08-13
- **Target enrollment:** 979 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034095, "A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04034095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*